USFDA approves Biocon drug Pegfilgrastim from new Bengaluru facility

"This is a significant milepost in our journey of serving 5 million patients by FY22 and crossing a revenue milestone of $1 billion," said Christiane Hamacher, CEO, Biocon Biologics.

from Moneycontrol Business News https://ift.tt/33pTd7m